Evidence map›Paper›PMID 36265887›Full record

ArticleJournal of breast cancer2022

Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis.

Zohreh Sanaat, Ozra Nouri, Monireh Khanzadeh, Hadi Mostafaei, Nafiseh Vahed, Neda Kabiri, Reza Ali Akbari Khoei, Hanieh Salehi-Pourmehr

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Zohreh SanaatHematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-1231-175X
Ozra NouriResearch Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-5613-2868
Monireh KhanzadehStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-4539-0685
Hadi MostafaeiDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID https://orcid.org/0000-0001-5596-1771
Nafiseh VahedResearch Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-6544-5014
Neda KabiriResearch Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0001-7224-9583
Reza Ali Akbari KhoeiResearch Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0002-6523-9640
Hanieh Salehi-PourmehrResearch Center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran. salehiha@tbzmed.ac.ir.ORCID https://orcid.org/0000-0001-9030-2106
Tabriz University of Medical Sciences · IRComprehensive Cancer Center Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBisphosphonates (BPs) have a powerful effect on reducing bone resorption and improving the survival of patients with breast cancer. We aimed to investigate the impact of BP treatment on the prevention of recurrence, metastasis, and death of breast cancer survivors in the perimenopausal period.

methodsThe search strategy aimed to identify both published and unpublished studies in PubMed, Web of Science, Scopus, Embase, ProQuest, and Google Scholar in March 2021. Two independent reviewers assessed quantitative papers selected for retrieval for methodological validity before being included in the review using standardized critical appraisal instruments from the Joanna Briggs Institute (JBI) Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI). Statistical meta-analysis was performed using Review Manager (RevMan) 5.4 statistical software when the data were homogenous. Meta-analysis was performed by calculating the effect size (hazard ratio; HR) and 95% confidence intervals (CIs).

resultsTwenty-one studies were eligible for this systematic review and meta-analysis. The overall The HRs for disease-free survival (DFS) and overall survival (OS) in women who received BPs were 0.89 (95% CI, 0.83-0.97;

conclusionAlthough BPs have a promising effect on DFS, OS, and bone metastasis of perimenopausal women survivors of breast cancer, more RCTs are needed to evaluate their effect on other survivors' outcomes.

Indexed as

Breast NeoplasmsDiphosphonatesMenopauseRecurrenceSystematic Review

Identifiers

PMID36265887
PMCPMC9807326
OpenAlexW4307032582

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.